Forest to acquire U.S. rights to Merck’s Saphris sublingual tablets
Forest Laboratories Holdings Ltd., a subsidiary of Forest Laboratories Inc., plans to buy the exclusive U.S. rights for Saphris sublingual tablets, a medication for schizophrenia or acute bipolar mania, from Merck Sharp & Dohme B.V., a unit of Merck & Co.